Medpace Holdings Inc (MEDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medpace Holdings Inc (MEDP) has a cash flow conversion efficiency ratio of 0.420x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($192.65 Million) by net assets ($459.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Medpace Holdings Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Medpace Holdings Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Medpace Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Medpace Holdings Inc (MEDP) net assets for net asset value and shareholders' equity analysis.
Medpace Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medpace Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Invesco Plc
NYSE:IVZ
|
0.016x |
|
DT Midstream Inc
NYSE:DTM
|
0.060x |
|
SON.HO.UN.ADR 1/5 SF -05
F:PHBA
|
N/A |
|
Sinopac Financial Holdings Co Ltd
TW:2890
|
0.289x |
|
TELE2 AB UNSP.ADR/1/2 B
F:NCY
|
0.118x |
|
Sociedad Quimica y Minera de Chile SA ADR B
NYSE:SQM
|
0.078x |
|
CARLSBERG B DK20 ADR 1/5
F:CBGC
|
N/A |
|
Gfl Environmental Holdings Inc
TO:GFL
|
0.021x |
Annual Cash Flow Conversion Efficiency for Medpace Holdings Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medpace Holdings Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Medpace Holdings Inc (MEDP) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.07 Million | $713.22 Million | 1.554x | +110.67% |
| 2024-12-31 | $825.54 Million | $608.82 Million | 0.737x | -4.88% |
| 2023-12-31 | $558.95 Million | $433.37 Million | 0.775x | -22.80% |
| 2022-12-31 | $386.39 Million | $388.05 Million | 1.004x | +263.44% |
| 2021-12-31 | $952.93 Million | $263.33 Million | 0.276x | -13.92% |
| 2020-12-31 | $805.78 Million | $258.68 Million | 0.321x | +15.50% |
| 2019-12-31 | $726.28 Million | $201.87 Million | 0.278x | +4.68% |
| 2018-12-31 | $589.70 Million | $156.58 Million | 0.266x | +37.29% |
| 2017-12-31 | $503.53 Million | $97.39 Million | 0.193x | +28.76% |
| 2016-12-31 | $610.71 Million | $91.73 Million | 0.150x | -27.67% |
| 2015-12-31 | $413.47 Million | $85.87 Million | 0.208x | +11.01% |
| 2014-12-31 | $401.97 Million | $75.20 Million | 0.187x | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more